Stockscreener 앱 받기
2.11
20.08%
-0.53
시간 외 거래:
2.11
전일 마감가:
$2.64
열려 있는:
$1.905
하루 거래량:
43.38M
Relative Volume:
2.48
시가총액:
$704.60M
수익:
$32.77M
순이익/손실:
$-440.22M
주가수익비율:
-1.2635
EPS:
-1.67
순현금흐름:
$-400.48M
1주 성능:
-21.27%
1개월 성능:
+19.21%
6개월 성능:
-62.92%
1년 성능:
-73.43%
1일 변동 폭
$1.90
$2.30
1주일 범위
$1.90
$2.92
52주 변동 폭
$1.6385
$12.51
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
명칭
Iovance Biotherapeutics Inc
전화
(650) 260-7120
주소
825 INDUSTRIAL ROAD, SAN CARLOS
IOVA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
2.11 | 861.55M | 32.77M | -440.22M | -400.48M | -1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-15 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-05-16 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-05-12 | 다운그레이드 | Truist | Buy → Hold |
| 2025-05-09 | 다운그레이드 | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-07-29 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-11-20 | 개시 | Goldman | Buy |
| 2023-09-18 | 재확인 | Barclays | Overweight |
| 2023-05-30 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-03-27 | 재개 | Wells Fargo | Equal Weight |
| 2023-01-27 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-12-09 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-10-31 | 개시 | Guggenheim | Neutral |
| 2022-08-18 | 재개 | Wells Fargo | Equal Weight |
| 2022-01-28 | 업그레이드 | Stifel | Hold → Buy |
| 2021-12-07 | 재개 | Cowen | Outperform |
| 2021-06-10 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2021-05-20 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-05-19 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2021-05-19 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-05-03 | 개시 | Truist | Buy |
| 2021-04-16 | 개시 | Goldman | Buy |
| 2021-03-08 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-12-15 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-10-06 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-04-22 | 개시 | Mizuho | Buy |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-02-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-02-26 | 재확인 | Oppenheimer | Outperform |
| 2019-12-18 | 개시 | JMP Securities | Mkt Outperform |
| 2019-10-01 | 개시 | Stifel | Buy |
| 2019-04-29 | 개시 | Piper Jaffray | Overweight |
| 2019-02-28 | 재확인 | Chardan Capital Markets | Buy |
| 2019-02-07 | 개시 | Robert W. Baird | Outperform |
| 2018-12-31 | 재개 | B. Riley FBR | Buy |
| 2018-07-06 | 재확인 | Chardan Capital Markets | Buy |
| 2018-04-10 | 업그레이드 | B. Riley FBR, Inc. | Neutral → Buy |
| 2018-03-13 | 재확인 | B. Riley FBR, Inc. | Neutral |
| 2018-02-23 | 다운그레이드 | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-01-25 | 재확인 | H.C. Wainwright | Buy |
| 2017-11-01 | 재확인 | B. Riley FBR, Inc. | Buy |
모두보기
Iovance Biotherapeutics Inc 주식(IOVA)의 최신 뉴스
Iovance Biotherapeutics' Strategic Turnaround and Regulatory Hurdles: Is the Biotech Buyable at a 64% YTD Decline? - AInvest
Iovance Biotherapeutics' Q2 2025 Earnings Miss and Strategic Restructuring: A Turning Point or Deepening Crisis? - AInvest
Iovance Biotherapeutics Second Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q2 2025 Earnings Call Transcript - Insider Monkey
Measuring Iovance Biotherapeutics Inc.’s beta against major indicesAlgorithmic Prediction of Market Breakouts - Newser
Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates - MSN
How to escape a deep drawdown in Iovance Biotherapeutics Inc.Free Step-by-Step Trade Signal Implementation - Newser
Reversal indicators forming on Iovance Biotherapeutics Inc. stockDownside Control Plan With Support Analysis - Newser
3 Stocks That Could Turn $1,000 Into $5,000 by 2030 - Mitrade
3 Stocks That Could Turn $1,000 Into $5,000 by 2030 - The Motley Fool
Key resistance and support levels for Iovance Biotherapeutics Inc.Free Capital Growth With Controlled Risk Picks - Newser
How to escape a deep drawdown in Iovance Biotherapeutics IncPredictive Screener for Daily Trade Watch - Newser
Is Iovance Biotherapeutics Inc. stock bottoming outReal Time Trade Execution Alert Plan - Newser
Real time social sentiment graph for Iovance Biotherapeutics Inc.Trading Volume Anomaly Summary and Insight - Newser
Why Iovance Biotherapeutics Stock Plummeted Today - AOL.com
IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi - sharewise.com
Iovance falls after missing Q2 expectation - MSN
Iovance falls after missing Q2 expectation (IOVA:NASDAQ) - Seeking Alpha
Goldman Sachs Downgrades Iovance Biotherapeutics Amid Lawsuit Turmoil - StocksToTrade
Iovance Shares Dip as CFO Changes and Legal Troubles Mount - timothysykes.com
Iovance Bio updates on Amtagvi - The Pharma Letter
Why Iovance Biotherapeutics Stock Is Under Pressure? - StocksToTrade
Is Iovance’s Stock Plummet A Buying Chance? - timothysykes.com
Lacklustre Amtagvi launch forces Iovance to cut 19% of staff - FirstWord Pharma
Building trade automation scripts for Iovance Biotherapeutics Inc.Daily Stock Forecast Powered by AI Tools - Newser
Earnings call transcript: Iovance Biotherapeutics Q2 2025 misses revenue forecast - Investing.com
Iovance Biotherapeutics Declines 29% In Premarket Trading: Here's What's Happening - Benzinga
Iovance Biotherapeutics Exceeds 100 Patient Milestone with Amtagvi Treatment for Advanced Melanoma, Q2 2025 Sales Reach $54 Million. - AInvest
Iovance outlines $250M–$300M 2025 revenue target as restructuring aims to boost margins and expand Amtagvi adoption - MSN
Iovance Biotherapeutics (IOVA): Navigating Cost-Cutting and Global Expansion to Unlock Value in TIL Therapies - AInvest
Iovance Biotherapeutics: Strategic Restructuring and Amtagvi's Long-Term Potential in Immuno-Oncology - AInvest
Transcript : Iovance Biotherapeutics, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Iovance Biotherapeutics Inc (IOVA) Q2 2025 Earnings Call Highlig - GuruFocus
How to forecast Iovance Biotherapeutics Inc. trends using time seriesTrade Flow Monitor with Volume Tracker - Newser
Iovance Biotherapeutics Reports Strong Revenue Growth in Q2 2025 - TipRanks
Iovance Biotherapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Iovance Biotherapeutics: Overcoming Revenue Shortfalls with Strategic Growth Initiatives - TipRanks
Bay Area biotech company once worth $4.4 billion lays off chunk of staff - SFGATE
IOVANCE BIOTHERAPEUTICS, INC. SEC 10-Q Report - TradingView
Iovance Biotherapeutics: Q2 Earnings Snapshot - News-Times
Iovance Biotherapeutics Reports Q2 2025 Financial Results - TipRanks
Iovance Biotherapeutics earnings missed by $0.05, revenue fell short of estimates - Investing.com
Iovance Biotherapeutics Q2 revenue up 60mln to 60mln; FY25 guidance reiterated. - AInvest
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025 - GlobeNewswire
Iovance Earnings: Revenue Soars 93% as Revolutionary Cancer Treatment Reaches Major Milestone - Stock Titan
Iovance Biotherapeutics Advances Lifileucel Study for Endometrial Cancer - TipRanks
Iovance Biotherapeutics to Cut Workforce by Less Than 20 Percent Amid Slower-Than-Expected Lifileucel Sales - geneonline.com
Iovance cuts staff amid slow sales start for ‘TIL’ cell therapy - BioPharma Dive
Real time social sentiment graph for Iovance Biotherapeutics IncRisk-Managed Swing Setup and Signal Analysis - Newser
Universal Beteiligungs und Servicegesellschaft mbH Buys Shares of 17,191 Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - Defense World
Chart based analysis of Iovance Biotherapeutics Inc. trendsFree Community Verified Stock Suggestions - Newser
Iovance Biotherapeutics Inc (IOVA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):